Comparison of high-dose Cisplatin-based chemoradiotherapy and Cetuximab-based bioradiotherapy for p16-positive oropharyngeal squamous cell carcinoma in the context of revised HPV-based staging |
| |
| Authors: | Bhattasali Onita Thompson Lester DR Abdalla Iman A Chen Jergin Iganej Shawn |
| |
| Institution: | 1. Department of Radiation Oncology, Southern California Permanente Medical Group, Los Angeles Medical Center, 4950 Sunset Boulevard, Los Angeles, CA, USA;2. Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, 5601 De Soto Ave, Woodland Hills, CA, USA;3. Department of Hematology/Oncology, Southern California Permanente Medical Group, Los Angeles Medical Center, 1515 North Vermont Avenue, Los Angeles, CA, USA |
| |
| Abstract: | Aim: To perform a comparison of Cisplatin vs. Cetuximab in p16-positive oropharyngeal squamous cell carcinoma (OPSCC) in the context of the revised HPV-based staging.Background: Previous reports comparing these agents in head and neck cancer have included heterogenous disease and p16-status.Materials and methods: A retrospective review was conducted from 2006 to 2016 of patients with p16-positive OPSCC who underwent definitive radiotherapy concurrent with either triweekly Cisplatin (n?=?251) or Cetuximab (n?=?40). AJCC 8th Edition staging was adapted.Results: Median follow-up for surviving patients was 40 months. On multivariate analysis for all-comers, comparing Cisplatin and Cetuximab, 3-year locoregional recurrence (LRR): 6% vs. 16% (p?=?0.07), 3-year distant metastasis (DM): 8% vs. 21% (p?=?0.04), 3-year overall recurrence rate (ORR): 11% vs. 29% (p?=?0.01), and 3-year cause-specific survival (CSS): 94% vs. 79% (p?=?0.06), respectively. On stage-based subgroup analysis, for stage I | |
| Keywords: | Oropharyngeal squamous cell carcinoma High-dose cisplatin Cetuximab p16-positive Radiation therapy |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
